Canakinumab for Behcet`s Disease Resistant to Standard Treatment (CanBeDisT)
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Canakinumab (Primary)
- Indications Behcet's syndrome
- Focus Therapeutic Use
- Acronyms CanBeDisT
- 19 Dec 2023 Status changed from recruiting to completed.
- 14 Mar 2012 Planned End Date changed to 2 Nov 2012.
- 14 Mar 2012 New trial record